EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Anti‐amyloid antibody treatments for Alzheimer's disease

Robert Perneczky iD, Geert Dom, Andrew Chan, Peter Falkai, Claudio Bassetti

European Journal of Neurology · 2024-02 · 31 (2)

DOI: 10.1111/ene.16049 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Neurology, online erschienen am 11.09.2023. Verfasst von Robert Perneczky und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapy, LMU Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 108-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our aim is to review the most recent evidence on novel antibody therapies for Alzheimer's disease directed against amyloid‐β. This is a joint statement of the European Association of Neurology and the European Psychiatric Association. After numerous unsuccessful endeavors to create a disease‐modifying therapy for Alzheimer's disease, substantial and consistent evidence supporting the clinical effectiveness of monoclonal antibodies aimed at amyloid‐β is finally emerging. The latest trials not only achieved their primary objective of slowing the progression of the disease over several months but also demonstrated positive secondary clinical outcomes and a decrease in amyloid‐β levels as observed through positron emission tomography scans. Taken as a whole, these findings mark a significant breakthrough by substantiating that reducing amyloid‐β yields tangible clinical benefits, beyond mere changes in biomarkers. Concurrently, the regular utilization of the new generation of drugs will determine whether statistical efficacy translates into clinically meaningful improvements. This may well signify the dawning of a new era in the development of drugs for Alzheimer's disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionHumansAmyloid beta-PeptidesTreatment OutcomeAntibodies, MonoclonalPositron-Emission TomographyBiomarkers

Stichwörter der Autor:innen

anti-amyloid immunisationfluid and imaging biomarkersmild cognitive impairment and dementiamonoclonal antibodiestreatment of cognitive decline

Substanzen

Amyloid beta-PeptidesAntibodies, MonoclonalBiomarkers

Autor:innen und Institutionen

  • Department of Psychiatry and Psychotherapy, LMU Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany.
  • German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
  • Munich Cluster for System Neurology (SyNergy), Munich, Germany.
  • Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
  • Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, London, UK.
  • Faculty of Medicine and Social Sciences, University of Antwerp, Wilrijk, Belgium.

ORCID-Profile: Robert Perneczky

Zitieren

APA

Perneczky, R., Dom, G., Chan, A., Falkai, P., & Bassetti, C. (2024). Anti‐amyloid antibody treatments for Alzheimer's disease. European Journal of Neurology, 31(2). https://doi.org/10.1111/ene.16049

Vancouver

Perneczky R, Dom G, Chan A, Falkai P, Bassetti C. Anti‐amyloid antibody treatments for Alzheimer's disease. European Journal of Neurology. 2024;31(2). doi:10.1111/ene.16049

BibTeX
@article{Perneczky2024,
  author = {Perneczky, Robert and Dom, Geert and Chan, Andrew and Falkai, Peter and Bassetti, Claudio},
  title = {Anti‐amyloid antibody treatments for Alzheimer's disease},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {2},
  doi = {10.1111/ene.16049}
}
Kostenlos starten →